Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Amyotrophic lateral sclerosis (ALS) is a rare and fatal neurodegenerative disease thought to be precipitated by genetic, environment and lifestyle factors. In the UK, whole genome sequencing has become available to all people living with ALS, regardless of their family history or age of onset of disease. However, there is currently no formal guidance on how to deliver genetic counseling and testing in busy mainstream clinics. This article offers practical suggestions to clinicians who may wish or need to discuss genomic testing. As more clinical trials and targeted gene therapies develop, it is likely that conversations will evolve, reflecting the dynamic nature of this important and complex field.

More information Original publication

DOI

10.1080/21678421.2025.2539895

Type

Journal article

Publication Date

2026-02-01T00:00:00+00:00

Volume

27

Pages

28 - 34

Total pages

6

Keywords

ALS, Genomic testing, MND, diagnostic, genetic counseling, mainstream clinics, Humans, Amyotrophic Lateral Sclerosis, Genetic Testing, Genetic Counseling, Genetic Predisposition to Disease